TY - JOUR
T1 - Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy
T2 - A Real-World Transverse Study
AU - Cortellini, Alessio
AU - Buti, Sebastiano
AU - Santini, Daniele
AU - Perrone, Fabiana
AU - Giusti, Raffaele
AU - Tiseo, Marcello
AU - Bersanelli, Melissa
AU - Michiara, Maria
AU - Grassadonia, Antonino
AU - Brocco, Davide
AU - Tinari, Nicola
AU - De Tursi, Michele
AU - Zoratto, Federica
AU - Veltri, Enzo
AU - Marconcini, Riccardo
AU - Malorgio, Francesco
AU - Garufi, Carlo
AU - Russano, Marco
AU - Anesi, Cecilia
AU - Zeppola, Tea
AU - Filetti, Marco
AU - Marchetti, Paolo
AU - Botticelli, Andrea
AU - Antonini Cappellini, Gian Carlo
AU - De Galitiis, Federica
AU - Vitale, Maria Giuseppa
AU - Sabbatini, Roberto
AU - Bracarda, Sergio
AU - Berardi, Rossana
AU - Rinaldi, Silvia
AU - Tudini, Marianna
AU - Silva, Rosa Rita
AU - Pireddu, Annagrazia
AU - Atzori, Francesco
AU - Chiari, Rita
AU - Ricciuti, Biagio
AU - Iacono, Daniela
AU - Migliorino, Maria Rita
AU - Rossi, Antonio
AU - Porzio, Giampiero
AU - Cannita, Katia
AU - Ciciarelli, Valeria
AU - Fargnoli, Maria Concetta
AU - Ascierto, Paolo Antonio
AU - Ficorella, Corrado
N1 - © AlphaMed Press 2019.
PY - 2019/6
Y1 - 2019/6
N2 - BACKGROUND: Patients with a history of autoimmune diseases (AIDs) have not usually been included in clinical trials with immune checkpoint inhibitors.MATERIALS AND METHODS: Consecutive patients with advanced cancer, treated with anti-programmed death-1 (PD-1) agents, were evaluated according to the presence of pre-existing AIDs. The incidence of immune-related adverse events (irAEs) and clinical outcomes were compared among subgroups.RESULTS: A total of 751 patients were enrolled; median age was 69 years. Primary tumors were as follows: non-small cell lung cancer, 492 (65.5%); melanoma, 159 (21.2%); kidney cancer, 94 (12.5%); and others, 6 (0.8%). Male/female ratio was 499/252. Eighty-five patients (11.3%) had pre-existing AIDs, further differentiated in clinically active (17.6%) and inactive (82.4%). Among patients with pre-existing AIDs, incidence of irAEs of any grade was significantly higher when compared with patients without AIDs (65.9% vs. 39.9%). At multivariate analysis, both inactive (p = .0005) and active pre-existing AIDs (p = .0162), female sex (p = .0004), and Eastern Cooperative Oncology Group Performance Status
AB - BACKGROUND: Patients with a history of autoimmune diseases (AIDs) have not usually been included in clinical trials with immune checkpoint inhibitors.MATERIALS AND METHODS: Consecutive patients with advanced cancer, treated with anti-programmed death-1 (PD-1) agents, were evaluated according to the presence of pre-existing AIDs. The incidence of immune-related adverse events (irAEs) and clinical outcomes were compared among subgroups.RESULTS: A total of 751 patients were enrolled; median age was 69 years. Primary tumors were as follows: non-small cell lung cancer, 492 (65.5%); melanoma, 159 (21.2%); kidney cancer, 94 (12.5%); and others, 6 (0.8%). Male/female ratio was 499/252. Eighty-five patients (11.3%) had pre-existing AIDs, further differentiated in clinically active (17.6%) and inactive (82.4%). Among patients with pre-existing AIDs, incidence of irAEs of any grade was significantly higher when compared with patients without AIDs (65.9% vs. 39.9%). At multivariate analysis, both inactive (p = .0005) and active pre-existing AIDs (p = .0162), female sex (p = .0004), and Eastern Cooperative Oncology Group Performance Status
U2 - 10.1634/theoncologist.2018-0618
DO - 10.1634/theoncologist.2018-0618
M3 - Article
VL - 24
SP - e327-e337
JO - Oncologist
JF - Oncologist
SN - 1083-7159
IS - 6
ER -